A PHASE 1 TRIAL OF THE PARP INHIBITOR VELIPARIB IN COMBINATION WITH INTRAPERITONEAL FLOXURIDINE (FUDR) IN EPITHELIAL OVARIAN CANCER

被引：0
|
作者：
Hendrickson, A. Wahner [1 ]
Powell, M. [2 ]
Mutch, D. [2 ]
Tanner, E. [3 ]
Cliby, W. [4 ]
Swisher, E. [5 ]
Ralya, A. [6 ]
Reid, J. [7 ]
Burton, J. [1 ]
Wagner, J. [1 ]
Strand, C. [8 ]
Allred, J. [8 ]
Haluska, P. [9 ]
Erlichman, C. [1 ]
Ivy, S. P. [10 ]
Kaufmann, S. [1 ]
Karnitz, L. [11 ]
机构：
[1] Mayo Clin, Med Oncol, Rochester, MN USA
[2] Washington Univ, Gynecol Surg, St Louis, MO 63110 USA
[3] Johns Hopkins Univ, Gynecol & Obstet, Baltimore, MD USA
[4] Mayo Clin, Obstet & Gynecol, Rochester, MN USA
[5] Univ Washington, Obstet & Gynecol, Seattle, WA 98195 USA
[6] IQVIA, Clin PK PD, Overland Pk, KS USA
[7] Mayo Clin, Pharmacol, Rochester, MN USA
[8] Mayo Clin, Biomed Stat, Rochester, MN USA
[9] Merck & Co Inc, Oncol, Rahway, NJ 07065 USA
[10] NCI, NIH, Invest Drug Branch, CTEP, Bethesda, MD 20892 USA
[11] Mayo Clin, Oncol Res, Rochester, MN USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS8-0369
引用
收藏
页码：460 / 461
页数：2
相关论文
共 50 条
  • [31] A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients
    Stodtmann, Sven
    Nuthalapati, Silpa
    Eckert, Doerthe
    Kasichayanula, Sreeneeranj
    Joshi, Rujuta
    Bach, Bruce A.
    Mensing, Sven
    Menon, Rajeev
    Xiong, Hao
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (09): : 1195 - 1205
  • [32] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
    Shah, Payal D.
    Wethington, Stephanie L.
    Pagan, Cheyenne
    Latif, Nawar
    Tanyi, Janos
    Martin, Lainie P.
    Morgan, Mark
    Burger, Robert A.
    Haggerty, Ashley
    Zarrin, Haley
    Rodriguez, Diego
    Domchek, Susan
    Drapkin, Ronny
    Shih, Ie-Ming
    Smith, Simon A.
    Dean, Emma
    Gaillard, Stephanie
    Armstrong, Deborah
    Torigian, Drew A.
    Hwang, Wei-Ting
    Giuntoli, Robert
    Simpkins, Fiona
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 246 - 253
  • [33] Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
    Lampert, Erika J.
    Zimmer, Alexandra
    Padget, Michelle
    Cimino-Mathews, Ashley
    Nair, Jayakumar R.
    Liu, Yingmiao
    Swisher, Elizabeth M.
    Hodge, James W.
    Nixon, Andrew B.
    Nichols, Erin
    Bagheri, Mohammad H.
    Levy, Elliott
    Radke, Marc R.
    Lipkowitz, Stanley
    Annunziata, Christina M.
    Taube, Janis M.
    Steinberg, Seth M.
    Lee, Jung-Min
    CLINICAL CANCER RESEARCH, 2020, 26 (16) : 4268 - 4279
  • [34] Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
    Tan, A. R.
    Toppmeyer, D.
    Stein, M. N.
    Moss, R. A.
    Gounder, M.
    Lindquist, D. C.
    Ji, J. J.
    Chen, A. P.
    Egorin, M. J.
    Kiesel, B.
    Beumer, J. H.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
    Mansoor Raza Mirza
    Troels K. Bergmann
    Morten Mau-Sørensen
    René dePont Christensen
    Elisabeth Åvall-Lundqvist
    Michael J. Birrer
    Morten Jørgensen
    Henrik Roed
    Susanne Malander
    Flemming Nielsen
    Ulrik Lassen
    Kim Brøsen
    Line Bjørge
    Johanna Mäenpää
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 791 - 798
  • [36] A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
    Mirza, Mansoor Raza
    Bergmann, Troels K.
    Mau-Sorensen, Morten
    Christensen, Rene dePont
    Avall-Lundqvist, Elisabeth
    Birrer, Michael J.
    Jorgensen, Morten
    Roed, Henrik
    Malander, Susanne
    Nielsen, Flemming
    Lassen, Ulrik
    Brosen, Kim
    Bjorge, Line
    Maenpaa, Johanna
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 791 - 798
  • [37] Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors
    Do, Khanh T.
    Kochupurakkal, Bose
    Kelland, Sarah
    de Jonge, Adrienne
    Hedglin, Jennifer
    Powers, Allison
    Quinn, Nicholas
    Gannon, Courtney
    Vuong, Loan
    Parmar, Kalindi
    Lazaro, Jean-Bernard
    D'Andrea, Alan D.
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4710 - 4716
  • [38] A phase II clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer
    Hendrickson, A. E. Wahner
    Costello, B.
    Jewell, A.
    Kennedy, V.
    Fleming, G.
    Corr, B.
    Taylor, S. E.
    Lea, J.
    Reid, J.
    Swisher, E.
    Satele, D.
    Allred, J.
    Lensing, J.
    Ivy, S. P.
    Erlichman, C.
    Adjei, A. A.
    Kaufmann, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 357 - 357
  • [39] A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.
    Isakoff, S. J.
    Overmoyer, B.
    Tung, N. M.
    Gelman, R. S.
    Habin, K.
    Qian, J.
    Giranda, V.
    Shepherd, S.
    Garber, J. E.
    Ellisen, L. W.
    Winer, E. P.
    Goss, P. E.
    CANCER RESEARCH, 2011, 71
  • [40] A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer
    Moore, Kathleen N.
    Miller, Austin
    Bell-McGuinn, Katherine M.
    Schilder, Russell J.
    Walker, Joan L.
    O'Cearbhaill, Roisin E.
    Guntupalli, Saketh R.
    Armstrong, Deborah K.
    Hagemann, Andrea R.
    Gray, Heidi J.
    Duska, Linda R.
    Mathews, Cara A.
    Chen, Alice
    O'Malley, David
    Gordon, Sarah
    Fracasso, Paula M.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 13 - 22
12345